METHOD OF EVALUATING EFFICIENCY OF PHAGOTHERAPY IN TREATMENT OF INFECTIONS DISEASES Russian patent published in 2017 - IPC G01N33/48 C12Q1/04 

FIELD: medicine.

SUBSTANCE: method involves taking biological material under study, introducing a commercial bacteriophage solution into the biological material under study, and determining the effectiveness of the interaction of the commercial bacteriophage with pathogenic microorganisms in the biological material under study. Before the surgery, identification of pathogenic microorganisms in the area of planned surgical intervention is carried out. Determining the concentration (titer) of the bacteriophage against pathogenic microorganisms in the biological material under study. Enter the first dose of commercial bacteriophage solution immediately after performing the surgical procedure. 18-24 hours after the administration of the first dose of the commercial bacteriophage solution, the biological material is sampled and the concentration (titer) of the bacteriophage in the biological material is determined. When establishing a caption of at least 10⁶ Pfu/ml, a conclusion about the effective effect of a commercial bacteriophage solution on the target pathogenic microorganism, is made. 18-24 hours after the administration of the first dose of the commercial bacteriophage solution, a second dose of commercial bacteriophage solution is administered, 18-24 hours after the second dose of the commercial bacteriophage solution, a third dose of commercial bacteriophage solution is administered. On the 4th-5th day after the surgical intervention, the biological material is sampled and the efficiency is evaluated by comparing the bacteriophage contained in the biological material under study with the commercial bacteriophage solution. In establishing the identity of the lytic activity, at least the first two tenfold dilutions of a commercial bacteriophage solution used to treat a patient with a bacteriophage present in the biological material under study from the patient, a conclusion about the effectiveness of phage therapy is made and administering a commercial bacteriophage solution until the pathogens are completely eliminated, is continued. The method allows for qualitative and quantitative control of the presence of bacteriophages, which leads to a more accurate interpretation of the results obtained; allows to monitor the concentration of bacteriophages of in vitro and in vivo conditions. Providing identification of the etiologically significant causative agent of the infectious process before the surgical intervention, which allows to immediately select the etiotropic bacteriophage strain.

EFFECT: allows to evaluate the effectiveness of phage therapy in the process of conducting it, it allows to establish bacteriophage activity in the wound and thereby to increase the evaluation of the effectiveness of phage therapy, the quality of the treatment process is increased, the risk of recurrence of the infection decreases.

2 tbl